MedTrace Logo

Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia

NCT06571448 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2026-04-24

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy，safety and tolerability of SR750 in patients with trigeminal neuralgia (TN). Patients will receive SR750 (study drug) or placebo for 6 weeks and keep a diary of daily pain. The study duration for each patient is up to 11 weeks.

Conditions

  • Trigeminal Neuralgia

Interventions

DRUG

SR750 tablet

SR750 high dose BID orally for 6 weeks

DRUG

SR750 tablet

SR750 low dose BID orally for 6 weeks

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Shanghai SIMR Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Bifa Fan, MD · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-16
Primary Completion
2026-01-26
Completion
2026-02-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06571448 on ClinicalTrials.gov